Plenary Talk 21st International Conference on Biological Inorganic Chemistry 2025

Metal complexes in cells: from the design of metal-based catalytic antioxidants as enzymes mimics to application in cells and in vivo (122292)

Clotilde Policar 1 , Nicolas Delsuc 1 , Hélène C. Bertrand 1 , Alice Balfourier 1 , Christine Rampon 1 , Michel Volovitch 1 , Sophie Vriz 1
  1. Laboratoire Chimie physique et chimie du vivant, CPCV, UMR8228, Ecole normale supérieure ENS-PSL, PSL university, Sorbonne université, CNRS, Paris, France

After a general introduction on bioinorganic chemistry, some of its history and of its current challenges [1], the talk will focus on the design of metal-based catalytic antioxidants.

Metal complexes are increasingly used for biological applications [2]. Cell penetration, cell distribution and speciation of the metal complexes in biological environment are important to their bio-activity. Because of the nature of biological media (high viscosity, molecular overcrowding, compartmented environment, or high content in Lewis bases and metal ions), their speciation (or nature) and activity can be impacted by cellular surroundings. It is therefore key to study metal complexes meant for therapeutic purposes directly in cells or biological environment and correlate bioactivity with information on intracellular distribution and speciation [1, 3].

The conference will describe a bio-inspired approach [4] for the design of catalytic antioxidants mimicking antioxidant enzymes, getting inspiration from superoxide dismutase [5–7] or catalase [8]. We will present how they can be studied directly in cells. These cellular approaches encompass evaluation of the bioactivity [5, 9, 10], imaging [5, 6], analyses of their speciation [10, 11], and evaluation of the cellular redox state by a redoxomic approach [12]. Two applications will be delineated more specifically: (a) their usage of the antioxidants as anti-inflammatory agents in a cellular model in link with inflammatory bowel diseases using bacteria for delivery in cells and in vivo [13]; (b) their usage to mitigate the side effects of Pt-based drugs and neuropathy effects [14].

  1. Policar C (2025) Bioinorganic chemistry: where from and where to? JBIC Accepted. https://doi.org/doi.org/10.1007/s00775-025-02112-1
  2. Farrer NJ, Sadler PJ (2011). In: Bioinorganic medicinal chemistry. Wiley-VCH, Weinheim, Germany, pp 1–47
  3. Policar C, et al. CRAS. https://doi.org/10.5802/crchim.339
  4. Policar C (2024) Bioinorganic Chemistry: A Field Where Biomimetism and Bioinspiration Are Central. Inorg Chem 63:23475–23478. https://doi.org/10.1021/acs.inorgchem.4c04868
  5. Mathieu E, et al (2017) InorgChem 56:2545–2555. https://doi.org/10.1021/acs.inorgchem.6b02695
  6. Mathieu E, et al (2020) ChemCommun 56:7885–7888. https://doi.org/10.1039/D0CC03398G
  7. Vincent A, et al (2020) ChemCommun 56:399–402. https://doi.org/10.1039/C9CC07920C
  8. Coulibaly K, et al (2021) InorgChem 60:9309–9319. https://doi.org/10.1021/acs.inorgchem.0c03718
  9. Vincent A, et al (2021) JInorgBiochem 219:111431. https://doi.org/10.1016/j.jinorgbio.2021.111431
  10. Schanne G, et al (2022) OxidMedCellLongev 2022:Article ID 3858122. https://doi.org/10.1155/2022/3858122
  11. Zoumpoulaki M, et al (2022) AngewChemIntEd 61:e202203066. https://doi.org/10.1002/ange.202203066
  12. Zoumpoulaki M, et al (2025) AngewChemIntEd n/a:e202422644. https://doi.org/10.1002/anie.202422644
  13. Schanne G, et al (2025) FreeRadRes, doi.org/10.1080/10715762.2025.2478121
  14. Prieux-Klotz C, et al (2022) IJMS 23:12938. https://doi.org/10.3390/ijms232112938